FOLFOXIRI/Avastin (bevacizumab) regimens (concurrent and sequential) versus FOLFOX/Avastin
in first-line in patients with metastatic colorectal cancer. Patients will be randomized to
receive Avastin 5 mg/kg intravenously every 2 weeks with either concurrent or sequential
FOLFOXIRI or with FOLFOX for 4 to 6 months of induction therapy, followed by maintenance
therapy with Avastin plus either leucovorin/5-fluorouracil or capecitabine until disease
progression occurs. After disease progression, patients will receive treatment with a
fluoropyrimidine-based chemotherapy plus Avastin.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: email@example.com
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.